OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s
discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.
American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing
cancer - ACS researchers aim to reduce colorectal cancer deaths by offering options to improve screening participation
AI Summary: American Cancer Society revised colorectal screening guidelines, elevating at‑home stool testing and clarifying the role of blood‑based assays. Recommendations stress broader access to noninvasive stool tests while urging cautious, limited use of blood tests where appropriate, aiming to expand screening uptake without sacrificing diagnostic accuracy or overwhelming follow‑up resources.
- ACS guideline update: expanding stool tests, cautious blood-test role (7)
- Blood-based detection and ctDNA: trials shaping screening and treatment (4)
- All Other Stories
ACS guideline update: expanding stool tests, cautious blood-test role
Blood-based detection and ctDNA: trials shaping screening and treatment
All Other Stories
Simple blood test could lead to personalized lung cancer treatment
medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…
AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.
- Blood tests for monitoring and personalizing lung cancer care (4)
- MCED trials and clinical benefit debate (4)
- Methylation liquid biopsy methods and applications (4)
- All Other Stories
Blood tests for monitoring and personalizing lung cancer care
MCED trials and clinical benefit debate
Methylation liquid biopsy methods and applications
All Other Stories
Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.
AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.
Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…
AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.
Skin cancer cases hit record high in the UK
Sydney Ghazarian / cancerresearchuk - New analysis shows that melanoma skin cancer rates in the UK have reached a new high of 20,000 cases per yearThe post Skin cancer cases hit record high in the UK appeared first on Cancer Research UK - Cancer News.
AI Summary: The UK has recorded its highest-ever number of skin cancer cases, with an alarming rise in the most dangerous presentations. Public health experts point to changing sun behaviours and inadequate sun protection as likely contributors. The surge signals strain on dermatology services and a need for clearer messaging—because sunscreen confusion apparently remains a public health hobby.
Canadian from hantavirus-hit cruise ship tests positive
bbc - The individual is one of four former passengers on the MV Hondius isolating on Vancouver Island, British Columbia.
AI Summary: A Canadian passenger tested positive after an Andes‑virus outbreak aboard a cruise ship, and French authorities report the strain matches known South American viruses. Public health teams began targeted testing, contact tracing and onboard monitoring as experts debate what constitutes “close contact,” balancing realistic containment with the mild panic such exotic pathogens tend to inspire.
- Canada confirms hantavirus cases; testing and isolation underway (3)
- Defining close contact: contact‑tracing challenges and outbreaks at sea (3)
- Sequencing shows South American strain; ship arrival and WHO stance (4)
- All Other Stories
Canada confirms hantavirus cases; testing and isolation underway
Defining close contact: contact‑tracing challenges and outbreaks at sea
Sequencing shows South American strain; ship arrival and WHO stance
All Other Stories
When should you get a mammogram? Conflicting advice makes it hard to know
medicalxpress - Deciding when to get routine mammograms is confusing. Some health groups recommend women begin at age 40 or 45 while another recently opted for age 50. They also differ on whether yearly or every other year is best.
AI Summary: Conflicting guidance about when to start and how often to perform mammography continues to confuse patients and clinicians, complicating shared decision‑making. Experts urge individualized risk assessment and clearer communication of benefits and harms to reduce both undertreatment and unnecessary anxiety, because apparently screening schedules enjoy being controversial.
- Patient confusion over mammogram timing (2)
- Risk-based screening: AI and trials (3)
- USPSTF political shake-up threatens screening guidance (4)
- All Other Stories
Patient confusion over mammogram timing
Risk-based screening: AI and trials
USPSTF political shake-up threatens screening guidance
All Other Stories
FDA clears 1st AI sepsis monitoring tool
Giles Bruce / beckershospitalreview - A tool from tech company Bayesian Health has become the first continuous AI sepsis monitor to gain FDA approval. The solution monitors hospital patients to detect deterioration and flag sepsis early on. The application was developed at Baltimore-based Joh…
AI Summary: Regulators have cleared the first AI‑driven sepsis early‑warning system for clinical deployment, enabling hospitals to use algorithmic alerts to identify patients at risk of deterioration earlier. The clearance opens the door for broader adoption of AI in acute care while renewing debates about clinical oversight, false alarms and integration into existing workflows.
PCOS has been officially renamed PMOS, and it’s a momentous move
newscientist - PCOS will now be known as PMOS (polyendocrine metabolic ovarian syndrome), and for Alice Klein, who has the conditon, it's been a long time coming
AI Summary: Medical experts have rebranded polycystic ovary syndrome as "polyendocrine metabolic ovarian syndrome" (PMOS) to better reflect its metabolic and endocrine drivers and improve diagnosis and treatment for about 170 million affected women worldwide. The change follows years of debate over an inaccurate name and aims to reduce misdiagnosis and guide more targeted care—because calling it something sensible might actually help.
Study reveals how parenting styles shape babies' willingness to help others
medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.
AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.
FDA approves blood test to guide breast cancer therapy
Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …
AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.
- ESMO Breast highlights and expert commentary (4)
- FDA clearances reshape diagnostics and therapies (3)
- Liquid biopsy, mutations and treatment resistance (4)
- All Other Stories
ESMO Breast highlights and expert commentary
FDA clearances reshape diagnostics and therapies
Liquid biopsy, mutations and treatment resistance
All Other Stories
National study examines genetic testing to inform follow-up care for cancer survivors
medicalxpress - Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those…
AI Summary: A national study has been launched to assess whether genetic testing can refine follow-up care for cancer survivors, tailoring surveillance to individual risk and potentially reducing unnecessary tests. The large-scale effort seeks to integrate genomic data into survivorship plans to better predict late effects and allocate resources to those most likely to benefit.
- Building survivorship standards, care and advocacy (4)
- Conferences, research and personalized cancer survivorship insights (4)
- National genetic-testing study and genomic implications for survivors (4)
- All Other Stories
Building survivorship standards, care and advocacy
Conferences, research and personalized cancer survivorship insights
National genetic-testing study and genomic implications for survivors
All Other Stories
3 Dead in Hantavirus Outbreak Aboard Cruise Ship, W.H.O. Says
Alexandra E. Petri / nytimes - One case of the infection has been confirmed in a laboratory, and there are five additional suspected cases, the organization said on Sunday.
AI Summary: A suspected hantavirus outbreak on an Atlantic cruise ship has been linked to three deaths, prompting a WHO-led investigation and urgent public-health follow-up. Authorities are coordinating testing, contact tracing and onboard inspections while reminding the public that hantaviruses are typically rodent-borne and can cause severe respiratory illness if unchecked.
- Hantavirus basics and cruise outbreak risks (7)
- Stranded MV Hondius: passengers and routing (3)
- WHO probes deaths, possible human transmission (4)
- All Other Stories
Hantavirus basics and cruise outbreak risks
Stranded MV Hondius: passengers and routing
WHO probes deaths, possible human transmission
All Other Stories
AI, face photos may predict cancer survival: Mass General Brigham study
Giles Bruce / beckershospitalreview - Using multiple photos from across a patient’s course of treatment in the FaceAge AI tool may be an even better predictor of survival than a single photo alone, a new Mass General Brigham study found. Researchers behind FaceAge, which uses AI to analyze a …
AI Summary: An AI model trained on clinical cohorts at Mass General Brigham can estimate biological aging from simple facial photos and links accelerated facial aging to poorer cancer survival. The research suggests noninvasive image-based signals could complement standard prognostic markers, offering a surprising, low-cost way to flag higher-risk patients earlier.
11 cancers on the rise in young people - scientists find first clue why it's happening
bbc - Researchers stress that simple lifestyle changes can still significantly reduce the risk of cancer.
AI Summary: New studies report rising incidence of several cancers among younger adults, with England data showing increases in bowel and ovarian cancers and researchers claiming early clues to underlying drivers. Scientists are calling for urgent investigation into environmental, lifestyle, and diagnostic factors, enhanced surveillance and prevention measures — because apparently youth is no longer a guarantee.
- New lab discoveries point to targeted, immune-based cancer therapies (4)
- Other health stories: infections, liver care, social impacts on youth (5)
- Prevention and screening gaps risk late diagnoses, experts warn (4)
- Younger adults facing rising cancers — investigators hunt environmental culprits (7)
- All Other Stories
New lab discoveries point to targeted, immune-based cancer therapies
Other health stories: infections, liver care, social impacts on youth
Prevention and screening gaps risk late diagnoses, experts warn
Younger adults facing rising cancers — investigators hunt environmental culprits
All Other Stories
First-Ever Smell Map Is a Breakthrough in Sensory Research, a Step to Help Us Tackle Loss of Smell
discovermagazine - Discover how smell receptors in our noses aren’t randomly arranged but are highly organized, offering new paths toward treating sensory impairment.
AI Summary: Scientists have produced the first high‑resolution olfactory map, charting how scent receptors and neural circuits are organized in the nose. The atlas exposes unexpected patterns in odor encoding, helps explain smell loss, and points to new diagnostic and therapeutic pathways — including potential early markers of Alzheimer’s‑related olfactory damage.
- Hidden nose atlas rewrites smell organization, flags Alzheimer links (4)
- New brain markers and tests for early Alzheimer detection (4)
- All Other Stories